Georgila Konstantina, Vyrla Dimitra, Drakos Elias
Department of Biology, Medical School, University of Crete, Heraklion, Voutes, 71110 Crete, Greece.
Department of Pathology, Medical School, University of Crete, Heraklion, Voutes, 71110 Crete, Greece.
Cancers (Basel). 2019 Aug 1;11(8):1097. doi: 10.3390/cancers11081097.
Apolipoprotein A-I (ApoA-I), the major protein component of high-density lipoproteins (HDL) is a multifunctional protein, involved in cholesterol traffic and inflammatory and immune response regulation. Many studies revealing alterations of ApoA-I during the development and progression of various types of cancer suggest that serum ApoA-I levels may represent a useful biomarker contributing to better estimation of cancer risk, early cancer diagnosis, follow up, and prognosis stratification of cancer patients. In addition, recent in vitro and animal studies disclose a more direct, tumor suppressive role of ApoA-I in cancer pathogenesis, which involves anti-inflammatory and immune-modulatory mechanisms. Herein, we review recent epidemiologic, clinicopathologic, and mechanistic studies investigating the role of ApoA-I in cancer biology, which suggest that enhancing the tumor suppressive activity of ApoA-I may contribute to better cancer prevention and treatment.
载脂蛋白A-I（ApoA-I）是高密度脂蛋白（HDL）的主要蛋白质成分，是一种多功能蛋白质，参与胆固醇转运以及炎症和免疫反应调节。许多研究揭示了在各类癌症的发生和发展过程中ApoA-I的变化，这表明血清ApoA-I水平可能是一种有用的生物标志物，有助于更好地评估癌症风险、早期癌症诊断、随访以及癌症患者的预后分层。此外，最近的体外和动物研究揭示了ApoA-I在癌症发病机制中更直接的肿瘤抑制作用，这涉及抗炎和免疫调节机制。在此，我们综述了最近关于ApoA-I在癌症生物学中作用的流行病学、临床病理学和机制研究，这些研究表明增强ApoA-I的肿瘤抑制活性可能有助于更好地预防和治疗癌症。
